Interleukin 10 gene promoter polymorphism and risk of diffuse large B cell lymphoma (DLBCL)
Purpose: Given the importance of understanding the genetic variations involved in the pathogenesis of non-Hodgkin’s lymphoma (NHL), this work was designed to study the impact of IL-10 (1082 G/A; rs1800896 and 819 C/T; rs1800871) gene promoter polymorphism on susceptibility of Egyptians to diffuse large B cell lymphoma (DLBCL); the major type of NHL. To the best of our knowledge, this study is the first one that examines IL-10 promoter polymorphism in DLBCL in Egyptians.
Methods: Genotyping polymorphism is performed using sequence-specific primers polymerase chain reaction (SSP-PCR) in 100 Egyptian DLBCL patients and 119 normal controls. Circulating plasma levels of IL-10 were measured using Enzyme-linked immunosorbent assay (ELISA).
Results: Insignificant change in IL-10 (1082 and 819) genotypes was recorded. Although A allele is slightly decreased in DLBCL patients, it did not reach statistical significance. GT haplotype was significantly elevated (P <0.05) in NHL patients. A significant linkage disequilibrium between the 1082 and 819 SNPs with D0 = 0.596 and r2= 0.1032 (P <0.001) was demonstrated. Significantly increased plasma IL-10 (P <0.01) was found which is positively correlated (r =0.307; P < 0.01) with the disease.
Conclusions: Taken together, our findings demonstrated that IL-10 promoter gene polymorphism (1082 and 819) may not have an influence on the clinical outcome of DLBCL, especially in terms of overall secretion level. Further investigations of other cytokine gene polymorphisms will lead to a better understanding of the disease’s biological background.
Keywords: NHL; DLBCL; SNP; IL-10; ELISA